EDNRA and neoplasm: According with a recurring theme in the utilization of molecularly targeting therapeutics that should target both tumor cells and microenvironment where tumor cells thrive, macitentan simultaneously targets cancer cells, which typically express ETAR, and stromal elements through ETBR, enhancing antitumour immune and anti-angiogenic mechanisms.